Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
Authors:
Abstract
This prospective, randomized, placebo-controlled trial tested green-lipped mussel oil (PCSO-524) added to sildenafil-based therapy in dogs with pulmonary hypertension (PH), mostly secondary to myxomatous mitral valve disease. After 70 days, owner-assessed exercise tolerance improved significantly in the PCSO-524 group (P = 0.009), and the improvement in coughing between Day 35 and Day 70 was greater than with placebo (P = 0.03). The tricuspid regurgitation pressure gradient (TRPG), an echocardiographic estimate of pulmonary arterial pressure, fell in all dogs (P = 0.001), with no difference between groups.
A Randomized, Placebo-Controlled, Blinded Clinical Trial Evaluating PCSO-524 as an Adjunctive Therapy for Noninfectious Pododermatitis in Rabbits
Abstract
This randomized, blinded, placebo-controlled trial tested green-lipped mussel oil (PCSO-524) added to standard care in rabbits with Grade 1–2 noninfectious pododermatitis. After 56 days, combined hind-limb lesion size fell significantly in the PCSO-524 group (98.6 → 53.2 mm², p = 0.002) but not in the placebo group (94.0 → 75.6 mm², p = 0.58). No adverse events were associated with PCSO-524.
Adjunctive Therapy With a Perna canaliculus and Euphausia superba Extract (EAB-277TM ) for Clinical Signs of Tracheal Collapse in Dogs: A Prospective, Randomized and Placebo-Controlled Exploratory Trial
ABSTRACT Background: Tracheal collapse is a common canine respiratory disease characterized by dorsoventral cartilage flattening, airway lumen narrowing and subsequent mucosal inflammation.
Objectives: To investigate the efficacy of EAB-277, a marine lipid extract combining Perna canaliculus (30 mg) and Euphausia superba (20 mg) as an adjunctive therapy in the management of tracheal collapse in dogs.
Methods: Forty-one dogs with confirmed tracheal collapse were randomly assigned to receive standard conventional medications plus either EAB-277 ( n = 21) or a placebo ( n = 20). The EAB-277 treatment protocol included a loading dose for the initial 14 days. Clinical signs and quality of life were assessed together with fluoroscopy, radiography, haematology and serum biochemistry on Days 0, 14, 28 and 56.
Results: Dogs receiving EAB-277 showed a significant improvement in exercise tolerance by Day 14. Concurrently, fluoroscopic analysis demonstrated significant reductions in the percentage change in tracheal luminal diameter across the cervical, thoracic inlet and intrathoracic regions by Day 14. Both groups showed significant improvements in cough scores throughout the study, with no statistical difference between the groups.
Conclusions: Although conventional medical therapy effectively manages the clinical signs of tracheal collapse, particularly cough, this study demonstrates that EAB-277 provides additional benefits by significantly improving exercise tolerance and reducing dynamic tracheal collapse at the cervical, thoracic inlet and intra-thoracic regions, which might have the potential to enhance airway health.
Keywords: airway collapse cough exercise tolerance krill oil omega-3 Perna canaliculus
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
